List of Excipients in Branded Drug ONYDA XR

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
NextWave Pharmaceuticals Inc	ONYDA XR	clonidine hydrochloride	24478-148	ANHYDROUS CITRIC ACID
NextWave Pharmaceuticals Inc	ONYDA XR	clonidine hydrochloride	24478-148	EDETATE DISODIUM
NextWave Pharmaceuticals Inc	ONYDA XR	clonidine hydrochloride	24478-148	GLYCERIN
NextWave Pharmaceuticals Inc	ONYDA XR	clonidine hydrochloride	24478-148	METHYLPARABEN
NextWave Pharmaceuticals Inc	ONYDA XR	clonidine hydrochloride	24478-148	POLYSORBATE 80
NextWave Pharmaceuticals Inc	ONYDA XR	clonidine hydrochloride	24478-148	POLYVINYL ACETATE

ONYDA XR Excipient Strategy and Commercial Opportunities

Last updated: August 7, 2026

ONYDA XR is a differentiated pediatric ADHD product built around clonidine hydrochloride, an established active ingredient, in a once-daily extended-release oral suspension. Its commercial value depends less on molecular exclusivity than on formulation performance, taste, dose uniformity, controlled release, dispensing accuracy, and the difficulty of reproducing the full liquid product.

Tris Pharma’s main excipient opportunity is the protection and optimization of a pediatric liquid platform. Suppliers can target controlled-release matrix materials, suspension stabilizers, taste-masking systems, preservatives, container-closure systems, and dosing devices. Generic competition is possible, but an extended-release suspension creates more technical and regulatory hurdles than an immediate-release clonidine tablet.

What is ONYDA XR and how does its formulation work?

ONYDA XR contains clonidine hydrochloride at a concentration of 0.1 mg/mL and is indicated for ADHD in patients aged 6 years and older, either as monotherapy or as adjunctive therapy to stimulant medications.[1]

Attribute	ONYDA XR
Active ingredient	Clonidine hydrochloride
Dosage form	Extended-release oral suspension
Strength	0.1 mg/mL
Route	Oral
FDA application	NDA 214628
Sponsor	Tris Pharma, Inc.
Indication	ADHD in patients age 6 and older
Dosing schedule	Once daily, typically at bedtime
Dose range	0.1 mg to 0.4 mg daily
FDA approval	2024
Product category	Small-molecule prescription drug
Biosimilar exposure	None

The product is designed for pediatric patients who may have difficulty swallowing tablets or capsules. Its liquid format also permits dose titration in 0.1 mg increments. The approved labeling requires shaking before use and provides an oral dosing syringe, making suspension homogeneity and dose-delivery accuracy central to product performance.[1]

The FDA label identifies inactive ingredients including citric acid monohydrate, glycerin, hypromellose, methylparaben sodium, microcrystalline cellulose, polysorbate 80, sodium citrate dihydrate, sodium saccharin, sorbitol, and water.[1]

The label does not assign a separate functional role to each excipient. Based on standard pharmaceutical use, the formulation appears to combine:

• A viscosity and controlled-release system, including hypromellose and cellulosic suspension components.
• Suspending and structuring agents, including microcrystalline cellulose and related polymeric materials.
• A wetting or dispersion aid, including polysorbate 80.
• Sweetening and taste-masking agents, including sorbitol and sodium saccharin.
• Buffering and pH-control components, including citric acid and sodium citrate.
• A preservative system, including methylparaben sodium.
• A humectant and mouthfeel modifier, including glycerin.

The commercial importance lies in the interaction among these ingredients. A substitute excipient may preserve viscosity while changing release kinetics, sedimentation, redispersibility, palatability, preservative performance, or syringe dosing.

What excipients are used in ONYDA XR?

The publicly identified ONYDA XR excipient system is:

Excipient	Likely formulation function	Commercial sensitivity
Hypromellose	Viscosity control, suspension structure, release modulation	Polymer grade and substitution can affect dissolution
Microcrystalline cellulose	Suspension structure and particle stabilization	Grade, particle size, and supplier changes can alter rheology
Polysorbate 80	Wetting and dispersion	Oxidation, impurity profile, and compatibility require control
Glycerin	Humectant, viscosity and mouthfeel modifier	Concentration affects taste, density, and flow
Sorbitol	Sweetener and bodying agent	Can affect osmolality, gastrointestinal tolerance, and taste
Sodium saccharin	High-intensity sweetener	Supports pediatric taste masking
Citric acid and sodium citrate	Buffer system and pH control	pH affects stability, preservative activity, and drug release
Methylparaben sodium	Antimicrobial preservation	Preservative efficacy and regulatory acceptability are critical
Purified water	Vehicle	Microbial and chemical quality determine batch performance

These ingredients are generally available pharmaceutical excipients rather than rare materials. The barrier is not basic ingredient access. The barrier is achieving the same formulation profile across particle size, viscosity, pH, preservative efficacy, dissolution, sedimentation, and dose uniformity.

How does ONYDA XR’s excipient strategy create commercial opportunities?

Controlled-release polymer supply

The highest-value excipient opportunity is the controlled-release and suspension polymer system. Hypromellose and microcrystalline cellulose are established materials, but pharmaceutical manufacturers often require tight control over:

• Viscosity grade.
• Substitution pattern.
• Particle size.
• Moisture content.
• Bulk density.
• Microbial limits.
• Metal and peroxide impurities.
• Lot-to-lot rheology.

A supplier that can provide a documented equivalent grade may compete for future commercial supply, but qualification will require more than compendial compliance. The manufacturer would need to demonstrate that the alternative maintains release kinetics and physical stability.

Polymer suppliers can also pursue co-development agreements covering:

• Custom viscosity grades.
• Pre-blended suspension systems.
• Low-shear dispersibility.
• Improved redispersibility after storage.
• Reduced sedimentation.
• Lower processing temperature.
• Better compatibility with preservatives and sweeteners.

Pediatric taste-masking systems

Pediatric adherence creates a direct commercial opportunity for flavor and taste-masking suppliers. Clonidine can produce an unpleasant sensory profile, while excipient changes may affect bitterness, aftertaste, mouth coating, and sweetness perception.

The most valuable solution is not simply a stronger flavor. It is a system that preserves:

• Palatability at the approved dose volume.
• Stability over shelf life.
• Compatibility with the preservative system.
• Suspension uniformity.
• Acceptance across pediatric age groups.
• No material change in absorption or release.

Flavor systems can also support line extensions, including lower-sugar formulations, sugar-free formulations, or products designed for patients with dietary restrictions. Any change to sweetener, flavor, buffer, or viscosity system could trigger comparative stability, dissolution, and clinical bridging requirements.

Preservative and microbial-control systems

ONYDA XR is an aqueous multidose product. Methylparaben sodium is listed in the formulation, making preservative efficacy a commercial and regulatory control point.

Potential supplier opportunities include:

• Higher-purity methylparaben sodium.
• Improved preservative dispersion.
• Alternative preservative systems.
• Container-closure systems that reduce microbial ingress.
• Multidose dispensing systems with reduced contamination risk.
• Manufacturing processes that lower bioburden without altering the suspension.

A preservative substitution would be commercially attractive only if it avoids changes in taste, pH, release profile, and pediatric tolerability. Preservative efficacy testing under USP <51> and product-specific stability studies would be necessary.[2]

What formulation patents protect ONYDA XR?

The core protection is likely to center on the extended-release clonidine suspension, its excipient combinations, release profile, and methods of treating ADHD. Tris Pharma has historically used formulation patents and platform technology to protect liquid extended-release products.

Potential claim categories include:

1. Composition claims covering clonidine hydrochloride with specified polymeric excipients, suspending agents, buffers, sweeteners, and preservative concentrations.
2. Performance claims covering dissolution or release over a defined time period.
3. Physical-property claims covering viscosity, particle size, sedimentation, redispersibility, or dose uniformity.
4. Method-of-use claims covering once-daily treatment of ADHD, adjunctive use with stimulants, or pediatric dosing.
5. Manufacturing claims covering order of addition, hydration of polymers, homogenization, or suspension processing.
6. Device-related claims covering the oral syringe, bottle, or dose-delivery configuration.

The product label is not a complete patent record. Patent numbers, expiration dates, terminal disclaimers, pediatric extensions, and Orange Book listing status must be assessed in the current FDA Orange Book and USPTO records.[3,4]

The key strategic point is that an excipient supplier may avoid direct infringement of a formulation patent by supplying a component, but a finished-product manufacturer remains exposed if its ANDA product practices the claimed formulation or manufacturing method.

When does ONYDA XR lose exclusivity?

Clonidine is an old active ingredient, so ONYDA XR does not receive new chemical entity exclusivity based on clonidine itself. The product may receive exclusivity associated with a new dosage form, new formulation, or supporting clinical investigations, subject to FDA’s Orange Book determination.[3]

The relevant exclusivity layers are:

Exclusivity or barrier	Relevance to ONYDA XR
New chemical entity exclusivity	Unlikely to apply because clonidine was previously approved
Three-year exclusivity	Potentially relevant if FDA recognized qualifying new clinical investigations
Pediatric exclusivity	Possible only if FDA granted it based on a written pediatric study request
Formulation patents	Potentially central to generic timing
Method-of-use patents	May affect labeling and skinny-label strategies
Trade secrets	May protect process parameters, supplier specifications, and sensory development
Regulatory complexity	Extended-release suspension testing may delay practical entry

A generic applicant can challenge listed patents through a Paragraph IV certification. The applicant must then demonstrate that the relevant patent is invalid, unenforceable, or not infringed. A successful Paragraph IV challenge can accelerate market entry, while a patent suit can impose a statutory stay of FDA approval for up to 30 months under the Hatch-Waxman framework.[5]

What Paragraph IV challenges and litigation risks exist?

ONYDA XR is a small-molecule product, so the principal challenge mechanism is an ANDA with Paragraph IV certifications rather than a biosimilar application.

Generic applicants are likely to examine:

• Whether the formulation claims require every listed excipient.
• Whether the claims require specific concentration ranges.
• Whether the release profile is claimed as a product characteristic.
• Whether a different polymer can avoid the claims.
• Whether method-of-use claims can be carved out through a skinny label.
• Whether the formulation is obvious in view of prior clonidine liquids and extended-release polymers.
• Whether the listed patents properly claim the approved product.

An ANDA applicant may pursue a formulation that uses different grades or concentrations of hypromellose, microcrystalline cellulose, sweetener, preservative, or surfactant. That approach can reduce literal infringement risk but may increase bioequivalence and CMC risk.

The most difficult litigation issues will likely involve functional formulation claims. A claim directed to a release profile, viscosity range, or suspension property can be harder to design around than a claim listing a narrow set of excipients.

No biosimilar litigation pathway applies because clonidine hydrochloride is a chemically synthesized small molecule, not a biologic regulated under the Public Health Service Act.

What is the FDA regulatory status of ONYDA XR?

FDA approved ONYDA XR in 2024 for ADHD in patients at least 6 years old.[1] It is a prescription extended-release suspension administered once daily, generally at bedtime. The labeling permits gradual weekly dose increases and requires tapering rather than abrupt discontinuation because clonidine withdrawal may cause rebound hypertension.[1]

Regulatory issues relevant to excipient development include:

• Demonstration of pharmaceutical equivalence.
• Comparative dissolution and release testing.
• Suspension uniformity after storage and shaking.
• Dose accuracy across the bottle life.
• Preservative efficacy.
• Extractables and leachables.
• Pediatric acceptability.
• Stability after opening.
• Container-closure integrity.
• Compatibility with the dosing syringe.

For a generic product, the FDA may require comparative in vitro and in vivo data because extended-release liquid suspensions can have complex release behavior. The applicant must show that excipient changes do not create clinically meaningful differences in exposure or release.

How strong is the ONYDA XR patent estate?

The patent estate is stronger against straightforward copy products than against carefully engineered formulation alternatives.

Strengths

• Extended-release liquid clonidine is a narrower product category than immediate-release clonidine tablets.
• Pediatric suspension performance creates multiple claim dimensions.
• A formulation can be protected through composition, process, performance, and use claims.
• The dosing device and multidose presentation may add commercial differentiation.
• Generic applicants face formulation-specific bioequivalence and stability work.

Weaknesses

• Clonidine is an old active ingredient with extensive prior art.
• Most listed excipients are standard pharmaceutical materials.
• Generic applicants may substitute polymer grades or excipient concentrations.
• Method-of-use claims may be vulnerable to skinny-label strategies.
• A successful formulation patent challenge could remove the primary barrier to entry.

The estate is strongest when claims require a defined combination of excipients and a measurable release or physical-stability profile. It is weaker when claims rely on broad, conventional excipient classes without a demonstrated technical effect.

What manufacturing and intellectual-property barriers affect generic entry?

Manufacturing scale-up is a meaningful barrier because suspension performance can change with mixing energy, order of addition, hydration time, temperature, shear, and hold time.

Critical manufacturing controls include:

• Polymer hydration.
• Uniform dispersion of clonidine-containing particles.
• Prevention of agglomeration.
• Control of air entrainment.
• Viscosity development.
• pH adjustment.
• Preservation.
• Homogeneous filling.
• Reproducible syringe dose delivery.

A generic manufacturer must also source qualified excipients at commercial scale. A supplier change may require comparability studies, updated stability work, and regulatory notification. This creates opportunities for dual-source excipient suppliers, but it also limits rapid substitution.

Trade-secret protection may be significant even where patent claims are narrow. Process conditions, mixing sequence, polymer hydration protocols, flavor composition, and acceptance criteria may not appear in the public label or patent claims.

How does ONYDA XR compare with competing ADHD products?

Product category	Example	Dosage form	Key commercial advantage
ONYDA XR	Clonidine hydrochloride	Extended-release oral suspension	Liquid dosing and nonstimulant therapy
Kapvay	Clonidine hydrochloride	Extended-release tablet	Established clonidine brand and tablet format
Intuniv	Guanfacine hydrochloride	Extended-release tablet	Nonstimulant alpha-2A agonist
Stimulant liquids	Methylphenidate or amphetamine products	Liquid or suspension	Strong efficacy and flexible dosing
Stimulant chewables or ODTs	Various products	Chewable or orally disintegrating	Swallowing convenience

ONYDA XR occupies a narrower but commercially important position: pediatric nonstimulant treatment in a liquid format. Its excipient strategy supports patients who cannot reliably swallow tablets and allows bedtime dosing. The main competitive risk comes from generic or branded liquid stimulants, not only from clonidine tablets.

What licensing opportunities exist for ONYDA XR excipients?

The most credible licensing targets are platform technologies that improve product performance without changing the active ingredient.

Potential deal structures include:

• Exclusive supply of a specified polymer grade.
• Co-development of a taste-masking system.
• Regional licensing of a pediatric suspension platform.
• Dual-source qualification agreements.
• Manufacturing licenses for premixed excipient concentrates.
• Device and container-closure partnerships.
• Reformulation licenses for sugar-free or preservative-reduced versions.

A supplier seeking strategic value should offer a package that includes regulatory documentation, analytical methods, scale-up support, stability data, and supply assurance. Commodity excipient supply alone is less likely to command meaningful licensing economics.

What generic launch scenarios exist for ONYDA XR?

Scenario 1: Patent-protected delay

The first ANDA applicant files a Paragraph IV certification, Tris Pharma initiates litigation, and FDA approval is delayed by the statutory stay and patent outcome. Commercial entry could be postponed until patent expiry, settlement, or a successful invalidity or noninfringement judgment.

Scenario 2: Formulation design-around

A generic manufacturer uses a different polymer grade or excipient ratio while matching the approved release profile. This reduces direct infringement risk but increases development and FDA review complexity.

Scenario 3: Skinny-label entry

A generic applicant removes protected method-of-use language while retaining the nonprotected ADHD indication. This strategy depends on the scope and enforceability of the listed method patents.

Scenario 4: Authorized generic or license

Tris Pharma or a commercial partner could authorize a generic version before full patent expiry. This would allow control over pricing, channel access, and erosion of the branded product.

Key Takeaways

• ONYDA XR’s commercial differentiation is its once-daily clonidine extended-release suspension for pediatric ADHD.
• The excipient system combines polymers, suspension stabilizers, sweeteners, buffers, a preservative, and a surfactant.
• The largest supplier opportunities are controlled-release polymers, pediatric taste masking, preservative systems, and dispensing technology.
• Clonidine’s prior approval history limits chemical exclusivity. Formulation patents, regulatory exclusivity, and manufacturing know-how carry greater weight.
• Generic entry will require more than duplicating the active ingredient. Suspension uniformity, release kinetics, taste, preservation, and dose accuracy are central barriers.
• Biosimilar risk does not apply. The relevant pathway is ANDA approval with potential Paragraph IV challenges.
• Patent strength depends on whether claims require specific excipient combinations and measurable performance characteristics.
• Licensing value will be highest for excipient systems supported by regulatory files, scale-up data, and demonstrated pediatric performance.

FAQs

Can ONYDA XR be reformulated without hypromellose?

A reformulation may be technically possible, but replacing hypromellose could change viscosity, sedimentation, redispersibility, dissolution, and pharmacokinetic performance. A generic or follow-on product would need to evaluate formulation equivalence and patent design-around risk.

Is ONYDA XR a biologic eligible for biosimilar competition?

No. ONYDA XR contains clonidine hydrochloride, a chemically synthesized small molecule. Competition would proceed through the generic-drug framework rather than the biosimilar pathway.

Why is the oral syringe important to ONYDA XR’s patent and commercial strategy?

The syringe supports accurate measurement of a low-volume pediatric dose. Its performance affects dose uniformity, usability, and product safety. Container and device claims may provide supplementary protection even if they are not the primary patent barrier.

Can a generic company use different sweeteners from ONYDA XR?

Potentially, but a sweetener change can affect taste, viscosity, osmolality, stability, and patient acceptance. The generic applicant must also evaluate whether the change affects bioequivalence or creates a different product profile.

Which ONYDA XR excipient has the highest strategic value?

The polymer and suspension system has the highest strategic value because it affects release, physical stability, and dose uniformity simultaneously. Taste-masking excipients are commercially important, but polymer performance is more likely to influence patentability and generic-development difficulty.

References

1. U.S. Food and Drug Administration. (2024). ONYDA XR (clonidine hydrochloride) extended-release oral suspension: Prescribing information. Tris Pharma, Inc.

2. United States Pharmacopeia. (2024). General chapter <51>: Antimicrobial effectiveness testing. USP-NF.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

4. United States Patent and Trademark Office. (2024). Patent Center. U.S. Department of Commerce.

5. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No. 98-417, 98 Stat. 1585.